ICI-VPH: Impact of dosing schedules with Human papillomavirus vaccine [Impact Des Calendriers d'Immunisation Contre Les HPV]
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 31 Jul 2018
Price : $35 *
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Human papillomavirus infections
- Focus Therapeutic Use
- 02 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 04 Feb 2015 Planned number of patients is 4000 as reported by ClinicalTrials.gov record.
- 22 Dec 2013 New trial record